Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.57 |
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 5/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30394181 | 0.83 | CKS1B (0.57) | GPR119CKS1BSKP1SKP2PANK3 | |
| SCHEMBL4724234 | 0.83 | CKS1B (0.57) | GPR119CKS1BSKP1SKP2PANK3 | |
| SCHEMBL14614610 | 0.83 | CKS1B (0.59) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL23560717 | 0.82 | MAP4K4 (0.52) | GPR119MAP4K4 | |
| SCHEMBL23561132 | 0.82 | MAP4K4 (0.52) | GPR119MAP4K4 | |
| SCHEMBL1432924 | 0.81 | GPR119 (0.57) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL3554489 | 0.81 | PANK3 (0.63) | GPR119CKS1BSKP1SKP2PANK3 | |
| SCHEMBL30874494 | 0.81 | GPR119 (0.81) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL30893576 | 0.81 | GPR119 (0.57) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL30546362 | 0.81 | PANK3 (0.63) | GPR119CKS1BSKP1SKP2PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4434985-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-115745971-B | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-118055933-A | Selective PARP1 inhibitors and uses thereof | 成都百裕制药股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023088408-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| CN-115745971-A | PARP7 inhibitor and application thereof | 重庆华森制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| WO-2021123291-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-24 | — | — | WO | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1919901-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | GPR119 2909/4885CKS1B 1357/4885SKP1 1597/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | GPR119 2909/4885CKS1B 1357/4885SKP1 1597/4885 |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | PARP1, PARP11, PARP12 | GPR119 1130/4885CKS1B 380/4885SKP1 650/4885 |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM5, GRM1, GRM2 | GPR119 90/4885CKS1B 3326/4885SKP1 1493/4885 |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, COASY | GPR119 68/4885CKS1B 826/4885SKP1 1319/4885 |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM2 | GPR119 90/4885CKS1B 3326/4885SKP1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.